Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries has got a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the Neutroval (granulocyte colony-stimulating factor) biologic license application (BLA).
Subscribe to our email newsletter
The FDA’s Neutroval CRL is for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.
Teva said that the CRL is related to the Neutroval application requested several items which it is reviewing and will work with the FDA to determine the appropriate next steps regarding this application.
Additionally, Teva said that they have not asked by the FDA for additional pre-marketing clinical trials to complete the review of the BLA.